



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/735,592	12/11/2003	Arthur M. Krieg	C 1037.70038US01	2533

7590 11/03/2006

Helen C. Lockhart, Ph.D.
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210

EXAMINER

MINNIFIELD, NITA M

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 11/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/735,592

Applicant(s)

KRIEG ET AL.

Examiner

N. M. Minnifield

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 July 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-37, 52, 63-65, 68, 69 and 75 is/are pending in the application.
- 4a) Of the above claim(s) 2-5, 11-16, 20-22, 25-37, 52, 63-65, 68, 69 and 75 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 6-10, 17-19, 23 and 24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) See Continuation Sheet are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 11 December 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) *2 pgs.*
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 7/9/04; 7/24/06. *26 pgs. total*

- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 2-5,11-16,20-22,25-37,52,63-65,68,69 and 75.

DETAILED ACTION

1. Applicant's election with traverse of Group I, claims 1, 6-10 and 13-24 and a species of $X_1 = A$, $X_2 = A$ and $N_1 = \text{ATTTTTTTTTTA}$ in the reply filed on July 27, 2006 is acknowledged. The traversal is on the grounds that the invention is directed to a class of compounds sharing common structural features and methods of using that class of compounds to induce an immune response for treating disorders affected by the immune system. The members of the class of compounds are oligonucleotides. The Examiner has indicated that Applicants must elect specific oligonucleotides falling within the claimed genus. The claimed class of oligonucleotides share a common structural motif, similar to a chemical structure and have common functional properties. A search and examination of the entire class of oligonucleotides would not require an undue burden because the oligonucleotides that are the subject matter of the claims are a related class of chemical compounds having a generic common structural entity.

This is not found persuasive because the functional properties of the oligonucleotides has not been set forth in the claims. Further, the generic oligonucleotide for Group I is set forth in claim and the variations for X_1 , X_2 and N_1 each set forth different products structurally, i.e. different species of the generic oligonucleotide of claim 1. The requirement is still deemed proper and is therefore made FINAL.

2. Claims 2-5, 11-16, 20-22, 25-37, 52, 63-65, 68, 69 and 75 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions and/or species, there being no allowable generic or

linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on July 27, 2006.

3. Claims 1, 6-10, 17-19 23 and 24 will be examined in the pending application.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1, 6-10, 17-19, 23 and 24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The claims are directed to a product, an oligonucleotide comprising a formula with different values for each component of the oligonucleotide (see claim 1 for example). The oligonucleotide has modified internucleotide linkages. Applicants have elected that species of oligonucleotide wherein $X_1 = A$, $X_2 = A$ and $N_1 = ATTTTTTTTTTA$. It would appear from a review of the oligonucleotides set forth in the specification that this oligonucleotide is SEQ ID NO: 45.

The structure of SEQ ID NO: 45 is known and disclosed, that being a nucleotide sequence containing 17 nucleic acids. However, it is noted that neither the specification nor the claims disclose the structure of the oligonucleotide set forth in claim 1. The recitation of comprising indicates that there are other structural components to the claimed oligonucleotide. The structure of the additional nucleic acids in the product, oligonucleotide, is not known. The oligonucleotide recited in the pending claimed genus would not clearly apprise one skilled in the art that the inventors had possession of the claimed genus and all species encompassed thereby as of the filing date. The structure of these oligonucleotides has not been specifically defined. Further, the claims do not set forth any function for the claimed oligonucleotides. The specification, at p. 2, l. 17-20, indicates, "The invention involves the finding that specific sub-classes of CpG immunostimulatory oligonucleotides having a 5'CpG are highly effective in mediating immune stimulatory effects. These CpG nucleic acids are useful therapeutically and prophylactically for stimulating the immune system to treat cancer, infectious diseases, allergy, asthma and other disorders and to help protect against opportunistic infections following cancer chemotherapy. The strong yet balanced, cellular and humoral immune responses that result from CpG stimulation reflect the body's own natural defense system against invading pathogens and cancerous cells." And that "oligonucleotides having a '5TCG motif without any additional unmethylated CpG motifs have strong immunostimulatory capability." (p. 2, l. 25-26) The claims do not set forth the specific structure of the claimed oligonucleotide and it is not clear if the claims or specification give the structure and a function of the oligonucleotide, as required by written description guidelines.

It is noted that the claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A biomolecule sequence described only by a functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence, normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence. An adequate written description of a chemical invention also requires a precise definition, such as by structure, formula, chemical name, or physical properties, and not merely a wish or plan for obtaining the chemical invention claimed.

A lack of adequate written description issue also arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a “laundry list” disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not “reasonably lead” those skilled in the art to any particular species); *In re Ruschig*, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967) (“If n-propylamine had been used in making the compound instead of n-butylamine, the compound of claim 13 would have resulted. Appellants submit to us, as they did to the board, an imaginary specific example patterned on specific example 6 by which the above butyl compound is made so that we can see what a simple change would have resulted in a specific supporting disclosure being present in the present specification. The trouble is that

there is no such disclosure, easy though it is to imagine it.”) (emphasis in original); *Purdue Pharma L.P. v. Faulding Inc.*, 230 F.3d 1320, 1328, 56 USPQ2d 1481, 1487 (Fed. Cir. 2000) (“the specification does not clearly disclose to the skilled artisan that the inventors ... considered the ratio... to be part of their invention There is therefore no force to Purdue’s argument that the written description requirement was satisfied because the disclosure revealed a broad invention from which the [later-filed] claims carved out a patentable portion”).

The claims are drawn to a vast genus of oligonucleotides. To fulfill the written description requirements set forth under 35 USC § 112, first paragraph, the specification must describe at least a substantial number of the members of the claimed genus, or alternatively describe a representative member of the claimed genus, which shares a particularly defining feature common to at least a substantial number of the members of the claimed genus, which would enable the skilled artisan to immediately recognize and distinguish its members from others, so as to reasonably convey to the skilled artisan that Applicant has possession the claimed invention.

MPEP § 2163.02 states, “[a]n objective standard for determining compliance with the written description requirement is, ‘does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed’ “. The courts have decided: The purpose of the “written description” requirement is broader than to merely explain how to “make and use”; the applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the “written description” inquiry, whatever is now claimed. See *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117

(Federal Circuit, 1991). Furthermore, the written description provision of 35 USC § 112 is severable from its enablement provision; and adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. The Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, paragraph 1, "Written Description" Requirement (66 FR 1099-1111, January 5, 2001) state, "[p]ossession may be shown in a variety of ways including description of an actual reduction to practice, or by showing the invention was 'ready for patenting' such as by disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention" (Id. at 1104). Moreover, because the claims encompass a genus of variant species, an adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus. However, factual evidence of an actual reduction to practice has not been disclosed by Applicant in the specification; nor has Applicant shown the invention was "ready for patenting" by disclosure of drawings or structural chemical formulas that show that the invention was complete; nor has Applicant described distinguishing identifying characteristics sufficient to show that Applicant were in possession of the claimed invention at the time the application was filed.

The introduction of claim changes which involve narrowing the claims by introducing elements or limitations which are not supported by the as-filed disclosure is a violation of the written description requirement of 35 U.S.C. 112, first paragraph. See, e.g., *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a “laundry list” disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not “reasonably lead” those skilled in the art to any particular species); *In re Ruschig*, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967) (“If n-propylamine had been used in making the compound instead of n-butylamine, the compound of claim 13 would have resulted. Appellants submit to us, as they did to the board, an imaginary specific example patterned on specific example 6 by which the above butyl compound is made so that we can see what a simple change would have resulted in a specific supporting disclosure being present in the present specification. The trouble is that there is no such disclosure, easy though it is to imagine it.”) (emphasis in original). In *Ex parte Ohshiro*, 14 USPQ2d 1750 (Bd. Pat. App. & Inter. 1989), the Board affirmed the rejection under 35 U.S.C. 112, first paragraph, of claims to an internal combustion engine which recited “at least one of said piston and said cylinder (head) having a recessed channel.” The Board held that the application, which disclosed a cylinder head with a recessed channel and a piston without a recessed channel did not specifically disclose the “species” of a channeled piston.

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 1, 6-10 and 17-19 are rejected under 35 U.S.C. 102(b) as being anticipated by Klinman et al (WO 00/61151; publication date Oct. 19, 2000).

The prior art discloses oligonucleotides comprising the formula, 5'TCGX₁X₂N₁3', as set forth in claim 1. Klinman et al discloses SEQ ID NO: 117, 119, 120, 133 and 135 that would be encompassed in the above formula (see attached pages from WO 00/61151). These sequences do not have an unmethylated CG motif in N₁ (pending claim 1). The sequences include at least one modified internucleotide linkage, Klinman et al at p. 18 (pending claims 6-8 and 10). The oligonucleotides of Klinman et al disclose that the oligonucleotide can be 20-100 nucleotides in length, see p. 3; p. 18 (pending claim 9). The oligonucleotides of Klinman et al disclose at least 50% and at least 80% pyrimidine (pending claims 17 and 18). The oligonucleotides of Klinman et al disclose that N₁ is free of Poly-A and Poly-G sequences (pending claim 19). The prior art anticipates the claimed invention.

Since the Patent Office does not have the facilities for examining and comparing applicants' oligonucleotides with the oligonucleotides of the prior art reference, the burden is upon applicants to show a distinction between the material structural and functional characteristics of the claimed oligonucleotides and the oligonucleotides of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

8. No claims are allowed.

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



N. M. Minnifield

Primary Examiner

Art Unit 1645

NMM
October 24, 2006

Pls. Mail w/ Action

<211> 12
<212> DNA
<213> synthetic

<400> 117

tcggctgttc tc

12

<210> 118
<211> 12
<212> DNA
<213> synthetic

<400> 118

tcgtctgttc tc

12

<210> 119
<211> 12
<212> DNA
<213> synthetic

<400> 119

tcgtgtgttc tc

12

<210> 120
<211> 12
<212> DNA
<213> synthetic

<400> 120

tcgcttggttc tc

12

<210> 121
<211> 12
<212> DNA
<213> synthetic

<400> 121

ttgttcgaac tc

12

<210> 122
<211> 12
<212> DNA
<213> synthetic

<400> 122

ttgttcgctc tc

12

<210> 123
<211> 12
<212> DNA
<213> synthetic

<400> 123

<212> DNA
<213> synthetic

<400> 130

ctcgtttggt ct

<210> 131
<211> 12
<212> DNA
<213> synthetic

<400> 131

ttcgtttggt ct

<210> 132
<211> 12
<212> DNA
<213> synthetic

<400> 132

cccgtttggt ct

<210> 133
<211> 12
<212> DNA
<213> synthetic

<400> 133

tgcgttggtc tc

<210> 134
<211> 11
<212> DNA
<213> synthetic

<400> 134

tgcgcaagg g

<210> 135
<211> 12
<212> DNA
<213> synthetic

<400> 135

tcgcccttgc tc

<210> 136
<211> 20
<212> DNA
<213> synthetic

<400> 136

*Pls mail
w/ Action*

12

12

12

12

11

12